In conclusion, the PK/PD model was successfully developed to quantify the exposure–response relationship and confirm the synergistic interaction of the combination therapy treating NSCLC with EGFR-TKI resistance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.